Patent
CATECHOLAMINE SURROGATES USEFUL AS β3 AGONISTS
William N. Washburn,Ravindar N. Girotra,Philip M. Sher,Amarendra B. Mikkilineni,Poss Kathleen M,Arvind Mathur,Ashvinikumar V. Gavai,Gregory S. Bisacchi +7 more
Reads0
Chats0
TLDR
In this paper, the authors present compounds of the formula "STR1" and pharmaceutically acceptable salts thereof, which are beta-three adrenergic receptor agonists and are useful in the treatment of diabetes, obesity and gastrointestinal diseases.Abstract:
Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. These compounds are beta three adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.read more
Citations
More filters
Patent
C-aryl glucoside SGLT2 inhibitors and method
TL;DR: In this article, an SGLT2 inhibiting compound is provided having the formula having the chemical structure, and a method is also provided for treating diabetes and related diseases employing an sGLT 2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Patent
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TL;DR: In this paper, the authors defined antidiabetic agents and anti-obesity agents with the following structure (i.e., where m is 0, 1 or 2; n is 0 or 1; Q is C or N; A is (CH2)x where x is 1 to 5; X is CH or N, X 2 is C, N, O or S; X 3 is C N, N O orS; X 4 is O N, S, O N or S, X 5 and X 6 is C.
Patent
Hmg-coa reductase inhibitors and method
TL;DR: In this paper, the HMG CoA reductase inhibitors are defined as HMG coA inhibitors that are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDl cholesterol, and treating hyperlipidemia.
Patent
Thyroid receptor ligands
Dennis E. Ryono,Jon J. Hangeland,Todd J. Friends,Tamara Dejneka,Pratik Devasthale,Yolanda Caringal,Minsheng Zhang,Arthur M. Doweyko,J. Malm,Andrei Sanin +9 more
TL;DR: New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R1 is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R2 and R3 are the same or different and are hydrogen, halogen and alkyls of 2 to 4 carbons respectively; R4 may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR
Patent
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
TL;DR: In this article, a method for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent was presented.
References
More filters
Patent
Ethanamine derivatives, their preparation and use in pharmaceutical compositions
Ainsworth A T,David Glynn Smith +1 more
TL;DR: The compounds of formula (II) have been found to possess anti-obesity and/or anti-hyperglycaemic activity as discussed by the authors, and the properties of these compounds have been investigated.
Patent
Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
TL;DR: The present invention discloses substituted 1,3-benzodioxoles which possess anti-diabetic and/or anti-hyperglycemic and anti-obesity properties in humans and other animals as discussed by the authors.
Journal ArticleDOI
Sulfonanilides. II. Analogs of Catecholamines
Aubrey A Larsen,William A. Gould,Herbert R Roth,William T. Comer,Robert H. Uloth,K. W. Dungan,P. M. Lish +6 more
Patent
5-[1-Hydroxy-2-(1-methyl-3-phenylpropyl)aminoethyl] salicylamide and physiologically acceptable acid addition salts thereof
TL;DR: In this paper, a blocking action on both α-and β-adrenergic receptors is described for acid addition salts of the STR1 formula, in which R 1 is A. an arylalkyl group, the alkyl portion of which contains from 1 to 6 carbon atoms, and the aryyl portion may be substituted by one or more alkoxy groups or hydroxy groups.
Patent
2-phenylethylamine derivatives
Richard Mark Hindley,John Berge +1 more
TL;DR: In this article, a pharmaceutically acceptable salt, ester or amide thereof, wherein: Ar is benzofuran-2-yl, or phenyl optionally substituted by groups R' and/or R2 wherein R' is halogen, trifluoromethyl or hydroxy and R2 is a halogen; R3 is hvdrogen or methyl; Xis- in which a is an integer from 1 to 6, b is aninteger from 2 to 7, M is hydroxy, C1-6 alkoxy, phen